3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
6
Urinary Bladder Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Gastrointestinal Neoplasms
1
Gastric or Gastroesophageal Cancer
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
32
Carboplatin
23
liposomal doxorubicin
14
pembrolizumab
12
Topotecan
10
Bevacizumab
10
Gemcitabine
9
mirvetuximab soravtansine
8
olaparib
6
Cisplatin
6
1-dodecylpyridoxal
6
rucaparib
5
Nivolumab
5
Cyclophosphamide
5
oregovomab
4
farletuzumab
3
catumaxomab
3
Standard of Care
3
Irinotecan
3
Fulvestrant
3
CCV-AV protocol
3
talazoparib
2
sacituzumab govitecan
2
ribociclib
2
phenoxodiol
2
pegfilgrastim
2
pazopanib
2
palbociclib
2
niraparib
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Ovarian Epithelial
×
bemarituzumab
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled